Needham & Company LLC Reiterates Buy Rating for Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham ...
Sarepta Therapeutics' SWOT analysis: gene therapy leader's stock faces pivotal year
Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...
Muscular Dystrophy News21h
Boys with DMD given Elevidys two years ago still showing motor gains
Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...
The American Journal of Managed Care21h
EMBARK 2: Delandistrogene Moxeparvovec Shows Sustained Benefits in DMD
The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years ...
precisionmedicineonline22h
Sarepta's DMD Gene Therapy Elevidys Shows Sustained Benefits in Updated Phase III Data
The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...
BMO maintains Outperform on Sarepta stock, $200 target
BMO Capital Markets sustained a favorable outlook on Sarepta Therapeutics (NASDAQ:SRPT), maintaining an Outperform rating and a $200.00 price target for the company's shares. Currently trading at $116 ...